Noble Mobile Acquires Helium Mobile Wireless Carrier
Noble Mobile has purchased Helium Mobile, a wireless carrier that operates a blockchain-based network. The transaction combines Noble's existing mobile service operations with Helium's decentralized infrastructure.
medium.comNoble Mobile has acquired Helium Mobile, a wireless carrier that runs a blockchain-based network. The deal merges Noble's mobile service business with Helium's decentralized wireless infrastructure. The transaction was announced on June 2, 2026. Terms of the acquisition were not disclosed.
Background on the Companies Noble Mobile provides mobile service to customers.
Helium Mobile operates a wireless network that uses blockchain technology to coordinate coverage from individual participants. The combined entity will integrate Noble's customer-facing operations with Helium's network model. No further details on integration plans or staffing changes were provided.
Transparency
2 independent outlets report the same core facts. This score blends how many outlets corroborate, their editorial tier, and how closely their facts agree — it measures corroboration, not proof.
Story details
Related Stories
thehindu.comU.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect
A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.
prnewswire.comFed Chairman Names Two Outside Advisers During Transition
Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.
insidermonkey.comForte Biosciences Accepts Resignation of Director David Veitch
Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…